13 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
ACP-204 in Adults With Alzheimer's Disease PsychosisHallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disordersRecruitingPhase 2 / Phase 32026-10-05NCT06159673
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaAgitation Associated With Alzheimer's DementiaRecruitingPhase 22026-09-29NCT06651567
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseaseAlzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 22026-09-29NCT06540833
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Psychosis Associated With Alzheimer's DiseaseRecruitingPhase 32026-09-29NCT05980949
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorderanxiety disorder, generalized anxiety disorder, psychiatric disorderRecruitingPhase 22026-09-25NCT06701903
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptomsdepressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 32026-09-25NCT06559306
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorderanxiety disorder, generalized anxiety disorder, psychiatric disorderRecruitingPhase 22026-09-25NCT06480383
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorderdepressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 32026-09-25NCT05850689
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-09-22NCT06585787
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeDyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, nervous system disorderActive, not recruitingPhase 32026-09-15NCT05397639
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Psychosis Associated With Alzheimer's DiseaseRecruitingPhase 32026-08-17NCT05511363
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyHallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disordersEnrolling by invitationPhase 32026-08-05NCT06194799
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)depressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 32026-07-24NCT07196501